Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31–46. https://doi.org/10.1158/2159-8290.CD-21-1059

Article  CAS  PubMed  Google Scholar 

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203–208. https://doi.org/10.1016/J.COI.2007.02.001

Article  CAS  PubMed  Google Scholar 

Galdiero MR, Bonavita E, Barajon I et al (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402–1410. https://doi.org/10.1016/J.IMBIO.2013.06.003

Article  CAS  PubMed  Google Scholar 

Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106. https://doi.org/10.1093/jnci/dju124

Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799. https://doi.org/10.1200/JCO.2008.21.4809

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296. https://doi.org/10.1200/JCO.20.1.289

Article  CAS  PubMed  Google Scholar 

Saal J, Bald T, Hölzel M et al (2022) In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Ann Oncol 33:982–984. https://doi.org/10.1016/j.annonc.2022.06.003

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290. https://doi.org/10.1056/nejmoa1712126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1816047

Article  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/nejmoa1816714

Article  CAS  PubMed  Google Scholar 

Xia L, Oyang L, Lin J et al (2021) The cancer metabolic reprogramming and immune response. Mol Cancer 201(20):1–21. https://doi.org/10.1186/S12943-021-01316-8

Article  Google Scholar 

Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW (2017) The immune system in cancer metastasis: friend or foe? J Immunother Cancer 5:79–79. https://doi.org/10.1186/S40425-017-0283-9

Article  PubMed  PubMed Central  Google Scholar 

Beypınar I, Sözel Y, Önder AH (2023) Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma. Cancer Biomark Preprint 1–11. https://doi.org/10.3233/CBM-230159

Sasaki A, Nakamura Y, Mishima S et al (2019) Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer

Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother CII 56:739–745. https://doi.org/10.1007/S00262-006-0272-1

Article  PubMed  Google Scholar 

Zhang Z, Li Y, Yan X et al (2019) Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Cancer Med 8:1467–1473. https://doi.org/10.1002/CAM4.2024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arkenau HT, Olmos D, Ang JE et al (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98:1029–1033. https://doi.org/10.1038/SJ.BJC.6604218

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garrido-Laguna I, Janku F, Vaklavas C et al (2012) Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118:1422–1428. https://doi.org/10.1002/CNCR.26413

Article  PubMed  Google Scholar 

Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89:284–290. https://doi.org/10.1038/SJ.BJC.6601038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye LC, Liu TS, Ren L et al (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol Off J Am Soc Clin Oncol 31:1931–1938. https://doi.org/10.1200/JCO.2012.44.8308

Article  CAS  Google Scholar 

Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet 387:1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4

Article  CAS  Google Scholar 

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). https://pubmed.ncbi.nlm.nih.gov/19097774/. Accessed 31 Jan 2025

van Dijk N, Funt SA, Blank CU et al (2019) The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur Urol 75:435–444. https://doi.org/10.1016/J.EURURO.2018.09.022

Article  PubMed  Google Scholar 

Tanizaki J, Haratani K, Hayashi H et al (2018) Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 13:97–105. https://doi.org/10.1016/J.JTHO.2017.10.030

Article  CAS  Google Scholar 

Simonaggio A, Elaidi R, Fournier L et al (2020) Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 69:2513–2522. https://doi.org/10.1007/S00262-020-02637-1/METRICS

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosner S, Kwong E, Shoushtari AN et al (2018) Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med 7:690–697. https://doi.org/10.1002/CAM4.1356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JT, Liu Y, Shabto JM et al (2021) Original research: Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Immunother Cancer 9:2851–2851. https://doi.org/10.1136/JITC-2021-002851

Article  Google Scholar 

Rebuzzi SE, Signori A, Banna GL et al (2021) Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol 13:17588359211019642. https://doi.org/10.1177/17588359211019642

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rebuzzi SE, Signori A, Buti S et al (2022) Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open 7:100634. https://doi.org/10.1016/j.esmoop.2022.100634

Article  CAS  PubMed  PubMed Central  Google Scholar 

Săftescu S, Șerban N, Volovăț S et al (2021) Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers. Exp Ther Med 21:605–605. https://doi.org/10.3892/etm.2021.10037

Article  CAS